JP2008515776A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008515776A5 JP2008515776A5 JP2007527730A JP2007527730A JP2008515776A5 JP 2008515776 A5 JP2008515776 A5 JP 2008515776A5 JP 2007527730 A JP2007527730 A JP 2007527730A JP 2007527730 A JP2007527730 A JP 2007527730A JP 2008515776 A5 JP2008515776 A5 JP 2008515776A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- antibody
- crystalline
- crystalline complex
- bound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001184 polypeptide Polymers 0.000 claims 62
- 102000004196 processed proteins & peptides Human genes 0.000 claims 62
- 108090000765 processed proteins & peptides Proteins 0.000 claims 62
- 238000000034 method Methods 0.000 claims 57
- 239000003795 chemical substances by application Substances 0.000 claims 27
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 claims 26
- 101710112663 Interleukin-13 receptor subunit alpha-1 Proteins 0.000 claims 26
- 239000003814 drug Substances 0.000 claims 25
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 24
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims 24
- 229940079593 drug Drugs 0.000 claims 24
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 claims 24
- 238000001727 in vivo Methods 0.000 claims 20
- 208000024891 symptom Diseases 0.000 claims 18
- 238000004590 computer program Methods 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 14
- 125000004429 atom Chemical group 0.000 claims 10
- 239000002131 composite material Substances 0.000 claims 10
- 125000004432 carbon atom Chemical group C* 0.000 claims 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 7
- 206010016654 Fibrosis Diseases 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 6
- 239000000556 agonist Substances 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 5
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 210000004204 blood vessel Anatomy 0.000 claims 4
- 210000002808 connective tissue Anatomy 0.000 claims 4
- 239000013078 crystal Substances 0.000 claims 4
- 229940000406 drug candidate Drugs 0.000 claims 4
- 230000004761 fibrosis Effects 0.000 claims 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 4
- 108040003607 interleukin-13 receptor activity proteins Proteins 0.000 claims 4
- 210000003491 skin Anatomy 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010014950 Eosinophilia Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 201000009961 allergic asthma Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 230000005784 autoimmunity Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 238000005094 computer simulation Methods 0.000 claims 2
- 238000009792 diffusion process Methods 0.000 claims 2
- 238000009510 drug design Methods 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 201000010659 intrinsic asthma Diseases 0.000 claims 2
- 230000003843 mucus production Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 210000002345 respiratory system Anatomy 0.000 claims 2
- 241000283707 Capra Species 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57873604P | 2004-06-09 | 2004-06-09 | |
| US57847304P | 2004-06-09 | 2004-06-09 | |
| US58137504P | 2004-06-22 | 2004-06-22 | |
| PCT/US2005/020334 WO2005121177A2 (en) | 2004-06-09 | 2005-06-09 | Anti-il-13 antibodies, crystals of anti-il-13 antibodies and complexes comprising them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008515776A JP2008515776A (ja) | 2008-05-15 |
| JP2008515776A5 true JP2008515776A5 (enExample) | 2008-07-24 |
Family
ID=35503715
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007527694A Expired - Fee Related JP4970258B2 (ja) | 2004-06-09 | 2005-06-09 | ヒトインターロイキン−１３に対する抗体およびそれらの使用 |
| JP2007527730A Withdrawn JP2008515776A (ja) | 2004-06-09 | 2005-06-09 | 抗ｉｌ−１３抗体、抗ｉｌ−１３抗体の結晶および該抗体を含有する複合体 |
| JP2011051866A Pending JP2011155980A (ja) | 2004-06-09 | 2011-03-09 | ヒトインターロイキン−１３に対する抗体およびそれらの使用 |
| JP2014167064A Pending JP2015037401A (ja) | 2004-06-09 | 2014-08-20 | ヒトインターロイキン−１３に対する抗体およびそれらの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007527694A Expired - Fee Related JP4970258B2 (ja) | 2004-06-09 | 2005-06-09 | ヒトインターロイキン−１３に対する抗体およびそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011051866A Pending JP2011155980A (ja) | 2004-06-09 | 2011-03-09 | ヒトインターロイキン−１３に対する抗体およびそれらの使用 |
| JP2014167064A Pending JP2015037401A (ja) | 2004-06-09 | 2014-08-20 | ヒトインターロイキン−１３に対する抗体およびそれらの使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7615213B2 (enExample) |
| EP (3) | EP1756161A2 (enExample) |
| JP (4) | JP4970258B2 (enExample) |
| KR (3) | KR20070034487A (enExample) |
| CN (2) | CN102827280A (enExample) |
| AR (2) | AR049390A1 (enExample) |
| AU (2) | AU2005252700A1 (enExample) |
| BR (2) | BRPI0511910A (enExample) |
| CA (2) | CA2567081A1 (enExample) |
| CR (2) | CR8783A (enExample) |
| EC (2) | ECSP067073A (enExample) |
| IL (2) | IL179093A0 (enExample) |
| MX (2) | MXPA06014298A (enExample) |
| NO (2) | NO20070087L (enExample) |
| NZ (1) | NZ582046A (enExample) |
| RU (2) | RU2427589C2 (enExample) |
| SG (2) | SG155260A1 (enExample) |
| TW (1) | TWI391133B (enExample) |
| WO (2) | WO2005123126A2 (enExample) |
Families Citing this family (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
| EP1444989A1 (en) * | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
| DK3718564T3 (da) | 2003-12-23 | 2023-11-06 | Genentech Inc | Nye anti-IL-13-antistoffer og anvendelser |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| JP2008520684A (ja) * | 2004-11-17 | 2008-06-19 | アブジェニックス・インコーポレーテッド | Ｉｌ−１３に対する完全ヒトモノクローナル抗体 |
| CN101198698B (zh) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | 通过调节多肽缔合制备多肽的方法 |
| WO2006113614A2 (en) * | 2005-04-15 | 2006-10-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Service National Institutes Of Health | Methods of treating and preventing inflammatory bowel disease involving il-13 and nkt cells |
| WO2007036745A2 (en) | 2005-09-30 | 2007-04-05 | Medimmune Limited | Interleukin-13 antibody composition |
| WO2007044450A2 (en) * | 2005-10-06 | 2007-04-19 | Baylor Research Institute | Compositions and methods for the treatment of cancer |
| US20070202106A1 (en) * | 2005-10-06 | 2007-08-30 | Baylor Research Institute | Compositions and methods for the treatment of cancer |
| EP1957530A2 (en) | 2005-10-21 | 2008-08-20 | Novartis AG | Human antibodies against il13 and therapeutic uses |
| DK1976877T4 (en) | 2005-11-30 | 2017-01-16 | Abbvie Inc | Monoclonal antibodies to amyloid beta protein and uses thereof |
| WO2007076062A2 (en) | 2005-12-21 | 2007-07-05 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
| BRPI0710572A2 (pt) * | 2006-01-24 | 2013-01-08 | Domantis Ltd | ligante, uso do ligante, mÉtodos para o tratamento de uma doenÇa alÉrgica, de asma e de cÂncer, para a inibiÇço de uma resposta imune do tipo th2, e administraÇço de tratamento anti-il-4 e tratamento anti-il-13, composiÇço farmacÊutica, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodos para a produÇço de um ligante e de inibiÇço da proliferaÇço de cÉlulas |
| SG170750A1 (en) | 2006-03-17 | 2011-05-30 | Biogen Idec Inc | Stabilized polypeptide compositions |
| EP3056568B1 (en) | 2006-03-31 | 2021-09-15 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| JP5144499B2 (ja) | 2006-03-31 | 2013-02-13 | 中外製薬株式会社 | 二重特異性抗体を精製するための抗体改変方法 |
| BRPI0713484A2 (pt) * | 2006-06-21 | 2012-11-06 | Apogenix Gmbh | expressão diferencial de citocina em cáncer humano |
| AU2007271349A1 (en) * | 2006-07-06 | 2008-01-10 | Apogenix Gmbh | Human IL-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy |
| KR101625961B1 (ko) * | 2006-09-08 | 2016-05-31 | 애브비 바하마스 리미티드 | 인터루킨-13 결합 단백질 |
| US7714111B2 (en) * | 2006-09-08 | 2010-05-11 | Wyeth Llc | Arginine derivative wash in protein purification using affinity chromatography |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| WO2008045563A2 (en) * | 2006-10-12 | 2008-04-17 | Wyeth | Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2684895A1 (en) | 2006-10-27 | 2014-01-15 | AbbVie Biotechnology Ltd | Crystalline anti-hTNFalpha antibodies |
| JP2010512402A (ja) * | 2006-12-11 | 2010-04-22 | ワイス エルエルシー | Ｉｌ−１３関連障害を治療するための方法および組成物ならびにその治療をモニター観察するための方法 |
| TW200837080A (en) * | 2007-01-09 | 2008-09-16 | Wyeth Corp | Anti-IL-13 antibody formulations and uses thereof |
| CA2675233A1 (en) | 2007-01-16 | 2008-07-24 | Abbott Laboratories | Methods for treating psoriasis |
| SI2426144T1 (sl) | 2007-02-23 | 2019-02-28 | Merck Sharp & Dohme Corp. | Umetno proizvedena anti-IL23P19 antitelesa |
| CN101663320A (zh) | 2007-02-23 | 2010-03-03 | 先灵公司 | 工程改造的抗IL-23p19抗体 |
| AU2008233173B2 (en) | 2007-03-29 | 2013-09-19 | Abbvie Inc. | Crystalline anti-human IL-12 antibodies |
| RU2009140134A (ru) * | 2007-04-23 | 2011-05-27 | Вайет (Us) | Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений |
| US7890055B1 (en) * | 2007-07-09 | 2011-02-15 | Everlokt Corporation | Touch field compound field detector personal ID |
| WO2009020654A1 (en) | 2007-08-08 | 2009-02-12 | Abbott Laboratories | Compositions and methods for crystallizing antibodies |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| RU2526512C2 (ru) | 2007-09-26 | 2014-08-20 | Чугаи Сейяку Кабусики Кайся | Модифицированная константная область антитела |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| JP2009106163A (ja) * | 2007-10-26 | 2009-05-21 | Kyushu Univ | 核酸配列、ベクター、形質転換体、製造方法、及び、核酸配列プライマー |
| EP2615115A3 (en) * | 2007-11-30 | 2014-01-08 | Glaxo Group Limited | Antigen-binding constructs |
| WO2009072604A1 (ja) | 2007-12-05 | 2009-06-11 | Chugai Seiyaku Kabushiki Kaisha | 抗nr10抗体、およびその利用 |
| TWI461210B (zh) | 2008-03-18 | 2014-11-21 | Abbvie Inc | 治療牛皮癬的方法 |
| BRPI0915825A2 (pt) | 2008-07-08 | 2015-11-03 | Abbott Lab | proteínas de ligação à prostaglandina e2 usos das mesmas |
| JP2012506695A (ja) | 2008-08-20 | 2012-03-22 | ヤンセン バイオテツク，インコーポレーテツド | 改変された抗ｉｌ−１３抗体、組成物、方法、及び使用 |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| EP2356154A4 (en) * | 2008-11-06 | 2012-12-19 | Alexion Pharma Inc | DEVELOPMENT OF REDUCED IMMUNOGENICITY ANTIBODIES AND METHODS OF MANUFACTURING THEREOF |
| GB0904214D0 (en) * | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
| JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
| EP2409990A4 (en) | 2009-03-19 | 2013-01-23 | Chugai Pharmaceutical Co Ltd | VARIANT OF A CONSTANT ANTIBODY REGION |
| KR20120024763A (ko) | 2009-05-15 | 2012-03-14 | 추가이 세이야쿠 가부시키가이샤 | 항ａｘｌ 항체 |
| US20120177668A1 (en) * | 2009-07-06 | 2012-07-12 | The Australian National University | Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor |
| WO2011037158A1 (ja) | 2009-09-24 | 2011-03-31 | 中外製薬株式会社 | 抗体定常領域改変体 |
| MX341136B (es) | 2009-10-20 | 2016-08-09 | Abbvie Inc | Aislamiento y purificacion de los anticuerpos anti-il-13 al usar la cromatografia de afinidad con proteina a. |
| WO2011108714A1 (ja) | 2010-03-04 | 2011-09-09 | 中外製薬株式会社 | 抗体定常領域改変体 |
| KR101860963B1 (ko) | 2010-04-23 | 2018-05-24 | 제넨테크, 인크. | 이종다량체 단백질의 생산 |
| KR101962483B1 (ko) | 2010-11-17 | 2019-03-29 | 추가이 세이야쿠 가부시키가이샤 | 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자 |
| EP3447491A3 (en) | 2010-12-16 | 2019-06-05 | F. Hoffmann-La Roche AG | Diagnosis and treatments relating to th2 inhibition |
| RU2013140685A (ru) | 2011-02-04 | 2015-03-10 | Дженентек, Инк. | ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
| US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
| CN112812184A (zh) | 2011-02-25 | 2021-05-18 | 中外制药株式会社 | FcγRIIb特异性Fc抗体 |
| AR085911A1 (es) | 2011-03-16 | 2013-11-06 | Sanofi Sa | Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual |
| CN103857411A (zh) | 2011-07-13 | 2014-06-11 | 阿布维公司 | 使用抗il-13抗体治疗哮喘的方法和组合物 |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| WO2013047748A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| WO2014004436A2 (en) | 2012-06-27 | 2014-01-03 | Merck Sharp & Dohme Corp. | Crystalline anti-human il-23 antibodies |
| KR101521224B1 (ko) * | 2012-12-20 | 2015-05-19 | 한양대학교 산학협력단 | T 세포 특이적인 인간화 단일조각항체 전달체 |
| EP2948134B1 (en) | 2013-01-24 | 2020-03-04 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mtor inhibitors |
| EP2981286A4 (en) * | 2013-04-05 | 2016-08-24 | Hoffmann La Roche | ANTI-IL-4 ANTIBODIES AND BISPECIFIC ANTIBODIES AND USES THEREOF |
| KR102571391B1 (ko) | 2013-09-13 | 2023-08-29 | 제넨테크, 인크. | 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물 |
| ES2915378T3 (es) | 2013-09-13 | 2022-06-22 | Hoffmann La Roche | Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares |
| AU2014325063B2 (en) | 2013-09-27 | 2019-10-31 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
| BR112016008694A2 (pt) | 2013-10-23 | 2017-10-03 | Genentech Inc | Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit |
| MX2016010729A (es) | 2014-02-21 | 2016-10-26 | Genentech Inc | Anticuerpos biespecificos anti-il-13 / il-17 y sus usos. |
| CN106471117A (zh) | 2014-05-06 | 2017-03-01 | 豪夫迈·罗氏有限公司 | 使用哺乳动物细胞产生异多聚体蛋白 |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| AR103162A1 (es) | 2014-12-19 | 2017-04-19 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-c5 y métodos para su uso |
| IL278014B2 (en) | 2014-12-19 | 2023-10-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use |
| SG10201907215QA (en) | 2015-02-05 | 2019-09-27 | Chugai Pharmaceutical Co Ltd | Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof |
| BR112017014067B1 (pt) | 2015-02-27 | 2021-01-12 | Chugai Seiyaku Kabushiki Kaisha | usos de um anticorpo receptor de il-6 para no tratamento de doenças relacionadas a il-6 |
| AR103726A1 (es) | 2015-02-27 | 2017-05-31 | Merck Sharp & Dohme | Cristales de anticuerpos monoclonales anti-pd-1 humanos |
| CA2977285A1 (en) | 2015-03-16 | 2016-09-22 | F. Hoffmann-La Roche Ag | Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases |
| WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| JP6871919B2 (ja) | 2015-06-16 | 2021-05-19 | ナノファギックス エルエルシー | 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法 |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
| BR112018009312A8 (pt) | 2015-12-28 | 2019-02-26 | Chugai Pharmaceutical Co Ltd | método para promover eficiência de purificação de polipeptídeo contendo região de fc |
| US11072666B2 (en) | 2016-03-14 | 2021-07-27 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
| KR102460040B1 (ko) | 2016-04-27 | 2022-11-01 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| SG11201807765PA (en) | 2016-04-28 | 2018-10-30 | Chugai Pharmaceutical Co Ltd | Antibody-containing preparation |
| CN109689099B (zh) | 2016-08-05 | 2023-02-28 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| CN118141914A (zh) * | 2016-09-01 | 2024-06-07 | 瑞泽恩制药公司 | 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法 |
| HRP20231015T1 (hr) | 2016-09-23 | 2023-12-08 | F. Hoffmann-La Roche Ag | Upotreba antagonista il-13 u liječenju atopičnog dermatitisa |
| JP7274417B2 (ja) | 2016-11-23 | 2023-05-16 | イミュノア・セラピューティクス・インコーポレイテッド | ４－１ｂｂ結合タンパク質及びその使用 |
| US10610104B2 (en) | 2016-12-07 | 2020-04-07 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| IL267869B2 (en) | 2017-01-06 | 2023-10-01 | Palvella Therapeutics Inc | Non-aqueous preparations of mTOR inhibitors and methods of use |
| CN108456250B (zh) * | 2017-02-17 | 2025-11-28 | 恺兴生命科技(上海)有限公司 | 靶向il-13ra2的抗体及其应用 |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
| US11845798B2 (en) | 2017-05-02 | 2023-12-19 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
| JP7185884B2 (ja) | 2017-05-02 | 2022-12-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CR20240273A (es) | 2017-11-01 | 2024-08-27 | Chugai Pharmaceutical Co Ltd | Variantes e isoformas de anticuerpos con actividad biológica reducida (divisional 2020-229) |
| CN109776677B (zh) * | 2017-11-15 | 2023-11-03 | 尚华科创投资管理（江苏）有限公司 | 一种人源化抗il-13抗体及其制备方法和应用 |
| WO2019157358A1 (en) | 2018-02-09 | 2019-08-15 | Genentech, Inc. | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
| GB201802487D0 (en) | 2018-02-15 | 2018-04-04 | Argenx Bvba | Cytokine combination therapy |
| MX2020009642A (es) | 2018-03-16 | 2021-01-08 | Zoetis Services Llc | Anticuerpos monoclonales de interleucina-31 para uso veterinario. |
| MX2020009639A (es) | 2018-03-16 | 2021-01-08 | Zoetis Services Llc | Vacunas de peptídos contra interleucina-31. |
| JP2021530463A (ja) | 2018-07-02 | 2021-11-11 | パルヴェラ セラピューティクス、インク． | ｍＴＯＲ阻害剤の無水組成物および使用方法 |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| KR20210089215A (ko) | 2018-11-07 | 2021-07-15 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항-pd-1 항체의 공동-제제 |
| WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| WO2020191346A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| AU2020247175A1 (en) * | 2019-03-26 | 2021-10-14 | Aslan Pharmaceuticals Pte Ltd | Treatment employing anti-IL-13R antibody or binding fragment thereof |
| JP2022549506A (ja) | 2019-09-27 | 2022-11-25 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症および関連状態を処置するための方法 |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| GB201919062D0 (en) * | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
| EP4149548A4 (en) | 2020-05-13 | 2024-05-08 | Disc Medicine, Inc. | ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS |
| CN118530356A (zh) * | 2020-12-08 | 2024-08-23 | 深圳福沃药业有限公司 | 抗il-13抗体及其用途 |
| CA3202832A1 (en) | 2020-12-31 | 2022-07-07 | Romesh R. Subramanian | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| IL305901A (en) | 2021-03-17 | 2023-11-01 | Receptos Llc | Methods for the treatment of atopic dermatitis using antibodies against IL-13 |
| WO2023044313A1 (en) | 2021-09-15 | 2023-03-23 | Dermira, Inc. | Il-13 inhibitors for the treatment of prurigo nodularis |
| WO2023091968A1 (en) | 2021-11-17 | 2023-05-25 | Disc Medicine, Inc. | Methods for treating anemia of kidney disease |
| CU20250005A7 (es) | 2022-06-17 | 2025-11-05 | Apogee Biologics Inc | Anticuerpos que se unen a interleuquina 13 |
| WO2024182714A1 (en) | 2023-03-02 | 2024-09-06 | Alloy Therapeutics, Inc. | Anti-cd22 antibodies and uses thereof |
| TW202525846A (zh) | 2023-08-25 | 2025-07-01 | 美商普羅特歐拉吉克適美國公司 | 抗ｉｌ—１３多特異性抗體構築體及其用途 |
| WO2025128990A1 (en) | 2023-12-14 | 2025-06-19 | Dermira, Inc. | Il-13 antibodies for the treatment of perennial allergic rhinitis |
| WO2025128984A1 (en) | 2023-12-14 | 2025-06-19 | Dermira, Inc. | Il-13 antibodies for the treatment of chronic rhinosinusitis with nasal polyps |
| WO2025184453A1 (en) | 2024-03-01 | 2025-09-04 | Dermira, Inc. | Il-13 antibodies for the treatment of post-inflammatory hyperpigmentation or hypopigmentation of skin |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0307434B2 (en) * | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| WO1989004838A1 (en) | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
| US5359037A (en) | 1988-09-12 | 1994-10-25 | Yeda Research And Development Co. Ltd. | Antibodies to TNF binding protein I |
| AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5011778A (en) | 1989-05-23 | 1991-04-30 | Otsuka Pharmaceutical Co., Ltd. | Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies |
| DE69026627T2 (de) | 1989-12-20 | 1996-08-22 | Schering Corp., Kenilworth, N.J. | Antikörperantagonisten gegen humanes interleukin-4 |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5246701A (en) | 1990-10-05 | 1993-09-21 | Ludwig Institute For Cancer Research | Method for inhibiting production of IgE by using IL-9 inhibitors |
| DE69206301T2 (de) | 1991-03-29 | 1996-06-13 | Sanofi, Paris | Protein mit der Aktivität vom Typ von Cytokin, dafür kodierende rekombinante DNS, transformierte Zellen und Mikroorganismen. |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| WO1993015766A1 (en) | 1992-02-10 | 1993-08-19 | Seragen, Inc. | Desensitization to specific allergens |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US5596072A (en) * | 1992-08-21 | 1997-01-21 | Schering Corporation | Method of refolding human IL-13 |
| WO1994004680A1 (en) | 1992-08-21 | 1994-03-03 | Schering Corporation | Human interleukin-13 |
| EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
| ATE188487T1 (de) | 1993-09-02 | 2000-01-15 | Dartmouth College | Anti-gp39 antikoerper und deren verwendungen |
| RU2162711C2 (ru) * | 1993-09-07 | 2001-02-10 | Смитклайн Бичам Корпорейшн | Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4 |
| US5928904A (en) | 1993-09-07 | 1999-07-27 | Smithkline Beecham Corporation | DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
| EP0659766A1 (en) | 1993-11-23 | 1995-06-28 | Schering-Plough | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| NZ292124A (en) | 1994-07-29 | 1998-10-28 | Smithkline Beecham Plc | Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment |
| GB9415379D0 (en) | 1994-07-29 | 1994-09-21 | Smithkline Beecham Plc | Novel compounds |
| US5696234A (en) | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
| US5705154A (en) | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| US20010053371A1 (en) | 1999-01-07 | 2001-12-20 | Waldemar Debinski | Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13 |
| US6911530B1 (en) | 1995-10-23 | 2005-06-28 | Amrad Operations, Pty., Ltd. | Haemopoietin receptor and genetic sequences encoding same |
| JP4224135B2 (ja) | 1995-10-23 | 2009-02-12 | ズィナイス セラピューティックス ピーティーワイ．エルティーディー． | 新規なヘモポエチン受容体およびそれをコードする遺伝子配列 |
| FR2742156A1 (fr) | 1995-12-06 | 1997-06-13 | Sanofi Sa | Polypeptide recepteur de l'il-13 |
| BRPI9707379C8 (pt) | 1996-02-09 | 2017-12-12 | Abbott Biotech Ltd | composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado. |
| US7078494B1 (en) | 1996-03-01 | 2006-07-18 | Genetics Institute, Llc | Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding |
| US6664227B1 (en) | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
| US5710023A (en) | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
| WO1997033913A1 (en) | 1996-03-13 | 1997-09-18 | Zymogenetics, Inc. | Cytokine-receptor expressed in testis cells |
| WO1997047741A1 (en) | 1996-06-12 | 1997-12-18 | Smithkline Beecham Corporation | Hr-1 receptor |
| EP0812913A3 (en) | 1996-06-12 | 1999-08-04 | Smithkline Beecham Corporation | HR-1 receptor, a receptor of the cytokine receptors family |
| WO1997047742A1 (en) | 1996-06-12 | 1997-12-18 | Smithkline Beecham Corporation | Hr-1 receptor |
| WO1998010638A1 (en) | 1996-09-10 | 1998-03-19 | Amrad Operations Pty. Ltd. | Therapeutic molecules |
| GB9625899D0 (en) | 1996-12-13 | 1997-01-29 | Glaxo Group Ltd | Substances and their uses |
| CA2277222A1 (en) | 1997-01-10 | 1998-07-16 | Biogen, Inc. | Treatment of lupus nephritis with anti-cd40l compounds |
| US6387615B2 (en) | 1997-04-11 | 2002-05-14 | Isis Innovation Limited | Methods and materials for the diagnosis or prognosis of asthma |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9723553D0 (en) | 1997-11-07 | 1998-01-07 | Duff Gordon W | Prediction of the risk of chronic obstructive airway disease |
| ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
| US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
| US6576232B1 (en) | 1998-04-03 | 2003-06-10 | The Penn State Research Foundation | IL13 mutants |
| US7083950B2 (en) | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
| WO2000036103A1 (en) | 1998-12-14 | 2000-06-22 | Genetics Institute, Inc. | Cytokine receptor chain |
| US7553487B2 (en) | 1998-12-14 | 2009-06-30 | Genetics Institute, Llc | Method and compositions for treating asthma |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| AU2460600A (en) | 1999-02-10 | 2000-08-29 | Mitsubishi Pharma Corporation | Amide compounds and medicinal use thereof |
| AU5756100A (en) | 1999-06-21 | 2001-01-09 | Genetics Institute Inc. | Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains |
| WO2001023410A2 (en) | 1999-09-28 | 2001-04-05 | Genaissance Pharmaceuticals, Inc. | Drug target isogenes: polymorphisms in the interleukin 13 gene |
| EP1222212A4 (en) | 1999-10-06 | 2005-05-04 | Penn State Res Found | MUTANTS OF IL-13 |
| GB0004016D0 (en) | 2000-02-22 | 2000-04-12 | Royal Brompton Hospital | Biological material and uses thereof |
| US6846486B1 (en) * | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
| EP1268794A2 (en) | 2000-04-07 | 2003-01-02 | Heska Corporation | Compositions and methods related to canine igg and canine il-13 receptors |
| MXPA02011682A (es) | 2000-05-26 | 2003-05-14 | Immunex Corp | Uso de antagonistas de interleuquina-4 y composiciones de los mismos. |
| AU8867501A (en) * | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| ES2311558T3 (es) | 2000-10-20 | 2009-02-16 | Genetics Institute, Inc. | Uso de inhibidores de la il-13 para el tratamiento de tumores. |
| EP2325205A3 (en) | 2000-12-28 | 2011-10-12 | Altus Pharmaceuticals Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| US6649935B2 (en) | 2001-02-28 | 2003-11-18 | International Business Machines Corporation | Self-aligned, planarized thin-film transistors, devices employing the same |
| GB0105360D0 (en) | 2001-03-03 | 2001-04-18 | Glaxo Group Ltd | Chimaeric immunogens |
| US7216242B2 (en) * | 2001-03-16 | 2007-05-08 | Dualcor Technologies, Inc. | Personal electronics device with appliance drive features |
| AUPR544401A0 (en) | 2001-06-04 | 2001-06-28 | Bischof, Robert Juergen | Animal model for allergy |
| EP1402451A4 (en) * | 2001-06-07 | 2005-01-05 | Wyeth Corp | SOLUTION STRUCTURE OF IL-13 AND USE THEREOF |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| US20030023555A1 (en) | 2001-07-26 | 2003-01-30 | Cashworks, Inc. | Method and system for providing financial services |
| CA2842429A1 (en) | 2001-10-19 | 2003-05-01 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders |
| US20040234499A1 (en) | 2001-10-26 | 2004-11-25 | David Shealy | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
| US20040248260A1 (en) | 2001-10-26 | 2004-12-09 | Heavner George A. | IL-13 mutein proteins, antibodies, compositions, methods and uses |
| EP1578912A4 (en) * | 2001-10-26 | 2007-12-26 | Centocor Inc | IL-13 MUTEIN PROTEINS, ANTIBODIES, COMPOSITIONS, METHODS AND USES |
| AU2002361122A1 (en) | 2001-11-27 | 2003-06-10 | Mochida Pharmaceutical Co., Ltd. | ANTI-IL13 RECEPTOR Alpha1 NEUTRALIZING ANTIBODY |
| WO2003047632A1 (en) | 2001-12-04 | 2003-06-12 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Chimeric molecule for the treatment of th2-like cytokine mediated disorders |
| EP1325868A1 (en) | 2002-01-08 | 2003-07-09 | Tetra Laval Holdings & Finance SA | Packaging unit for continuously producing sealed packages, containing pourable food products, from a tube of packaging material |
| WO2003080675A2 (en) | 2002-03-22 | 2003-10-02 | Amrad Operations Pty Ltd | MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-13 RECEPTOR ALPHA 1 (IL-13Rα1) |
| WO2003086451A1 (en) * | 2002-04-05 | 2003-10-23 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
| US6811780B2 (en) | 2002-05-01 | 2004-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of using cytokine antagonists to treat HIV infection and AIDS |
| ATE503233T1 (de) | 2002-06-14 | 2011-04-15 | Us Gov Health & Human Serv | Verfahren zur behandlung und prävention von kolitis, an der il-13 und nk-t zellen beteiligt sind |
| JP2004121218A (ja) * | 2002-08-06 | 2004-04-22 | Jenokkusu Soyaku Kenkyusho:Kk | 気管支喘息または慢性閉塞性肺疾患の検査方法 |
| WO2004019975A2 (en) * | 2002-08-30 | 2004-03-11 | Glaxo Group Limited | Il-14 vaccine for the treatment of asthma and atopic disorders |
| EP1576137A4 (en) | 2002-10-29 | 2010-06-30 | Genentech Inc | COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM |
| EP1572116A4 (en) | 2002-11-26 | 2007-12-12 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES |
| CA2508375C (en) | 2002-12-02 | 2014-05-27 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
| EP1444989A1 (en) | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| MXPA06000965A (es) | 2003-07-25 | 2007-05-04 | Silanes Sa De Cv Lab | Administracion de fragmentos f(ab??)2 de anticuerpos anti-citocinas. |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2005042028A2 (en) | 2003-10-27 | 2005-05-12 | Neopharm, Inc. | Il-13 conjugated to an immunogen and uses thereof |
| DK3718564T3 (da) | 2003-12-23 | 2023-11-06 | Genentech Inc | Nye anti-IL-13-antistoffer og anvendelser |
| RU2006126704A (ru) | 2003-12-24 | 2008-01-27 | Уайт (Us) | Способы лечения астмы |
| WO2005079755A2 (en) | 2004-02-12 | 2005-09-01 | Nektar Therapeutics | Interleukin-13 antagonist powders, spray-dried particles, and methods |
| EP1720573A4 (en) | 2004-02-27 | 2008-04-02 | Centocor Inc | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH IL-13 |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US20070048785A1 (en) | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| JP2010512402A (ja) | 2006-12-11 | 2010-04-22 | ワイス エルエルシー | Ｉｌ−１３関連障害を治療するための方法および組成物ならびにその治療をモニター観察するための方法 |
| RU2009140134A (ru) | 2007-04-23 | 2011-05-27 | Вайет (Us) | Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений |
-
2005
- 2005-06-08 AR ARP050102343A patent/AR049390A1/es active IP Right Grant
- 2005-06-09 AU AU2005252700A patent/AU2005252700A1/en not_active Withdrawn
- 2005-06-09 CN CN2012102800731A patent/CN102827280A/zh active Pending
- 2005-06-09 KR KR1020067025945A patent/KR20070034487A/ko not_active Withdrawn
- 2005-06-09 EP EP05786816A patent/EP1756161A2/en not_active Withdrawn
- 2005-06-09 JP JP2007527694A patent/JP4970258B2/ja not_active Expired - Fee Related
- 2005-06-09 CN CN2005800191385A patent/CN101141980B/zh not_active Expired - Fee Related
- 2005-06-09 BR BRPI0511910-3A patent/BRPI0511910A/pt not_active IP Right Cessation
- 2005-06-09 SG SG200905834-8A patent/SG155260A1/en unknown
- 2005-06-09 TW TW094119110A patent/TWI391133B/zh active
- 2005-06-09 NZ NZ582046A patent/NZ582046A/en not_active IP Right Cessation
- 2005-06-09 MX MXPA06014298A patent/MXPA06014298A/es unknown
- 2005-06-09 WO PCT/US2005/020160 patent/WO2005123126A2/en not_active Ceased
- 2005-06-09 MX MXPA06014299A patent/MXPA06014299A/es active IP Right Grant
- 2005-06-09 WO PCT/US2005/020334 patent/WO2005121177A2/en not_active Ceased
- 2005-06-09 AU AU2005253981A patent/AU2005253981B2/en not_active Ceased
- 2005-06-09 EP EP05786668A patent/EP1765401A4/en not_active Withdrawn
- 2005-06-09 EP EP12169663A patent/EP2548889A1/en not_active Withdrawn
- 2005-06-09 SG SG200706331-6A patent/SG135207A1/en unknown
- 2005-06-09 RU RU2006140793/10A patent/RU2427589C2/ru not_active IP Right Cessation
- 2005-06-09 BR BRPI0510881-0A patent/BRPI0510881A/pt not_active IP Right Cessation
- 2005-06-09 US US11/149,309 patent/US7615213B2/en not_active Expired - Fee Related
- 2005-06-09 JP JP2007527730A patent/JP2008515776A/ja not_active Withdrawn
- 2005-06-09 RU RU2006140096/13A patent/RU2006140096A/ru not_active Application Discontinuation
- 2005-06-09 KR KR1020067025990A patent/KR101299073B1/ko not_active Expired - Fee Related
- 2005-06-09 CA CA002567081A patent/CA2567081A1/en not_active Abandoned
- 2005-06-09 KR KR1020137008282A patent/KR101462878B1/ko not_active Expired - Fee Related
- 2005-06-09 CA CA002567129A patent/CA2567129A1/en not_active Abandoned
-
2006
- 2006-11-07 IL IL179093A patent/IL179093A0/en unknown
- 2006-11-22 IL IL179476A patent/IL179476A/en not_active IP Right Cessation
- 2006-12-05 CR CR8783A patent/CR8783A/es not_active Application Discontinuation
- 2006-12-05 CR CR8784A patent/CR8784A/es not_active Application Discontinuation
- 2006-12-11 EC EC2006007073A patent/ECSP067073A/es unknown
- 2006-12-11 EC EC2006007072A patent/ECSP067072A/es unknown
-
2007
- 2007-01-05 NO NO20070087A patent/NO20070087L/no not_active Application Discontinuation
- 2007-01-08 NO NO20070133A patent/NO20070133L/no unknown
-
2009
- 2009-10-08 US US12/575,896 patent/US8221752B2/en not_active Expired - Fee Related
-
2010
- 2010-08-17 AR ARP100103010A patent/AR077931A2/es unknown
-
2011
- 2011-03-09 JP JP2011051866A patent/JP2011155980A/ja active Pending
-
2014
- 2014-08-20 JP JP2014167064A patent/JP2015037401A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008515776A5 (enExample) | ||
| RU2006140096A (ru) | Анти-il-13 антитела и комплексы | |
| US11344621B2 (en) | Interleukin-13 binding proteins | |
| US8852593B2 (en) | Antagonist antibodies and their fab fragments against GPVI and uses thereof | |
| DK2504362T3 (en) | ANTI-C5A BINDING PARTS WITH HIGH BLOCKING ACTIVITY | |
| Li et al. | Omalizumab improves quality of life and asthma control in Chinese patients with moderate to severe asthma: a randomized phase III study | |
| JP6193871B2 (ja) | 慢性若しくは急性疾患又は急性病態に罹患している患者の臓器機能障害又は臓器不全を予防又は軽減するための、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| JP2016029027A (ja) | プロスタグランジンｅ２結合タンパク質およびこの使用 | |
| JP2014524733A5 (enExample) | ||
| JP2017522903A5 (enExample) | ||
| JP2017507139A (ja) | Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法 | |
| JP2009517057A5 (enExample) | ||
| CN101945891A (zh) | 治疗痛风的方法 | |
| RU2008152443A (ru) | Антитела высокой аффинности к il-6-рецептору человека | |
| JP2007097598A5 (enExample) | ||
| JP2017155050A (ja) | 慢性又は急性疾患に罹患している患者の体液平衡を調整するための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| JP2015502930A (ja) | 慢性若しくは急性疾患又は急性病態に罹患している患者の死亡リスクを低減するための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| JP2015502349A (ja) | 血液循環を安定化させるための、患者の急性疾患又は急性病態の治療法における使用に向けた、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| CN117098777A (zh) | 一种tslp抗原结合蛋白及其应用 | |
| JP2010521139A5 (enExample) | ||
| CA3190230A1 (en) | Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody | |
| HK1256740B (en) | Interleukin -13 binding proteins | |
| HK1128495B (en) | Interleukin -13 binding proteins | |
| HK1128495A (en) | Interleukin -13 binding proteins | |
| JPWO2022117526A5 (enExample) |